Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela
- Autores
- Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; Venezuela
Fil: Diaz Bello, Zoraida. Universidad Central de Venezuela; Venezuela
Fil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; Venezuela
Fil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; Venezuela
Fil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; Venezuela - Materia
-
CHAGAS DISEASE
ORAL TRANSMISSION
TRYPANOSOMA CRUZI
NIFURTIMOX - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/110255
Ver los metadatos del registro completo
id |
CONICETDig_82586250f0f0f62c6f67f1e9b5cf0fc4 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/110255 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, VenezuelaMuñoz Calderon, Arturo AlejandroDiaz Bello, ZoraidaRamirez, José LuisNoya, OscarAlarcón de Noya, BelkisyoléCHAGAS DISEASEORAL TRANSMISSIONTRYPANOSOMA CRUZINIFURTIMOXhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; VenezuelaFil: Diaz Bello, Zoraida. Universidad Central de Venezuela; VenezuelaFil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; VenezuelaFil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; VenezuelaFil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; VenezuelaMalaria Research Centre2019-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/110255Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-2430972-9062CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/0972-9062.289397info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/temp/JVectorBorneDis563237-9788681_024308.pdfinfo:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/downloadpdf.asp?issn=0972-9062;year=2019;volume=56;issue=3;spage=237;epage=243;aulast=Munoz-Calderon;type=2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:24:08Zoai:ri.conicet.gov.ar:11336/110255instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:24:08.425CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
title |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
spellingShingle |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela Muñoz Calderon, Arturo Alejandro CHAGAS DISEASE ORAL TRANSMISSION TRYPANOSOMA CRUZI NIFURTIMOX |
title_short |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
title_full |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
title_fullStr |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
title_full_unstemmed |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
title_sort |
Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela |
dc.creator.none.fl_str_mv |
Muñoz Calderon, Arturo Alejandro Diaz Bello, Zoraida Ramirez, José Luis Noya, Oscar Alarcón de Noya, Belkisyolé |
author |
Muñoz Calderon, Arturo Alejandro |
author_facet |
Muñoz Calderon, Arturo Alejandro Diaz Bello, Zoraida Ramirez, José Luis Noya, Oscar Alarcón de Noya, Belkisyolé |
author_role |
author |
author2 |
Diaz Bello, Zoraida Ramirez, José Luis Noya, Oscar Alarcón de Noya, Belkisyolé |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
CHAGAS DISEASE ORAL TRANSMISSION TRYPANOSOMA CRUZI NIFURTIMOX |
topic |
CHAGAS DISEASE ORAL TRANSMISSION TRYPANOSOMA CRUZI NIFURTIMOX |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite. Fil: Muñoz Calderon, Arturo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Central de Venezuela; Venezuela Fil: Diaz Bello, Zoraida. Universidad Central de Venezuela; Venezuela Fil: Ramirez, José Luis. Fundacion Instituto de Estudios Avanzados Idea; Venezuela Fil: Noya, Oscar. Universidad Central de Venezuela; Venezuela. Ministerio del Poder Popular para la Salud; Venezuela Fil: Alarcón de Noya, Belkisyolé. Universidad Central de Venezuela; Venezuela |
description |
Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. These results led us to examine whether parasite’s drug susceptibility was related to this therapeutic failure. Methods: The Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. The in vitro assays for drug testing were performed by the MTT methodology followed by calculation of inhibitory concentration-50 (IC50) values. Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 4.07 ± 1.82 to 94.92 ± 7.24 µM. Interpretation & conclusion: The high heterogeneity in nifurtimox IC50 values in the isolates and clones from the OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability that existed in the wild parasite population at the original source of contamination. Though, further pharmacological studies are needed to confirm the existence of natural nifurtimox resistance in the parasite. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/110255 Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-243 0972-9062 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/110255 |
identifier_str_mv |
Muñoz Calderon, Arturo Alejandro; Diaz Bello, Zoraida; Ramirez, José Luis; Noya, Oscar; Alarcón de Noya, Belkisyolé; Nifurtimox response of Trypanosoma cruzi isolates from an outbreak of Chagas disease in Caracas, Venezuela; Malaria Research Centre; Journal Of Vector Borne Diseases; 56; 3; 9-2019; 237-243 0972-9062 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.4103/0972-9062.289397 info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/temp/JVectorBorneDis563237-9788681_024308.pdf info:eu-repo/semantics/altIdentifier/url/http://www.jvbd.org/downloadpdf.asp?issn=0972-9062;year=2019;volume=56;issue=3;spage=237;epage=243;aulast=Munoz-Calderon;type=2 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Malaria Research Centre |
publisher.none.fl_str_mv |
Malaria Research Centre |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614237893165056 |
score |
13.070432 |